3rd Quarter - Report
CSL BEHRING LLC for CSL BEHRING LLC
Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Orphan drug exclusion from the branded annual pharmaceutical fee Medicare product access Appropriations report language specific to NIH
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN R. BULLARD | Sr. Manager, Federal Government Affairs |
| PATRICK COLLINS | Director, Healthcare Policy & External Affairs |
| DENNIS JACKMAN | Senior Vice President, Healthcare Policy & External Affairs |
Taxation/Internal Revenue Code TAX
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN R. BULLARD | Sr. Manager, Federal Government Affairs |
| PATRICK COLLINS | Director, Healthcare Policy and External Affairs |
| DENNIS JACKMAN | Senior Vice President, Healthcare Policy & External Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.